financetom
Business
financetom
/
Business
/
Market Chatter: Parkland Turned Down Takeover Offer From Sunoco Last Year Amid Shareholder Dispute
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: Parkland Turned Down Takeover Offer From Sunoco Last Year Amid Shareholder Dispute
Aug 9, 2024 8:36 AM

11:12 AM EDT, 08/09/2024 (MT Newswires) -- Calgary-based fuel retailer Parkland Corp. ( PKIUF ) rebuffed a takeover offer worth nearly $8-billion from Texas-based Sunoco LP ( SUN ) last year, The Globe and Mail has reported.

The proposal for a stock-based transaction was made in the summer of 2023 for $45 a share, according to a source familiar with the matter. That represented a roughly 28% premium to where Parkland shares were trading at the time and valued the Canadian company at about $7.9-billion. The Globe and Mail is not identifying the source because they were not authorized to discuss the bid publicly.

Parkland spokesperson Simon Scott said the company has a policy of not commenting on market speculation. The company disclosed this year that it received an offer in 2023, but provided no details on the bid's size or source, only that Parkland thought it undervalued the company.

(Market Chatter news is derived from conversations with market professionals globally, and/or from other media sources. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 36.05, Change: +0.71, Percent Change: +2.01

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts
Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts
Jan 13, 2025
Biogen Inc. ( BIIB ) submitted an unsolicited bid to acquire all of the outstanding shares of Sage Therapeutics Inc. ( SAGE ) that it does not already owned by Biogen for $7.22 per share. Goldman Sachs analyst Salveen Richter believes the proposal makes strategic sense, considering the financial success of the Zurzuvae launch for postpartum depression (PPD). Biogen says Zurzuvae exceeded its expectations. Also Read:...
Instacart, Uber Deal 'Makes More Sense Now,' Analyst Says: Here's Why
Instacart, Uber Deal 'Makes More Sense Now,' Analyst Says: Here's Why
Jan 13, 2025
Instacart parent company Maplebear Inc ( CART ) received an upgrade to Buy while also getting added to Needham’s conviction list on Monday as analysts expressed concern over increasing competition. What Happened: Needham analyst Bernie McTernan upgraded Maplebear ( CART ) from a Hold rating to a Buy rating. He also set a price target of $56, suggesting a nearly 30%...
AtriCure Shares Rise After Higher Q4, 2024 Revenue Projections; 2025 Revenue Outlook Set
AtriCure Shares Rise After Higher Q4, 2024 Revenue Projections; 2025 Revenue Outlook Set
Jan 13, 2025
02:32 PM EST, 01/13/2025 (MT Newswires) -- AtriCure ( ATRC ) shares were up 8% in recent Monday trading after the company said it expects higher revenue for Q4 and fiscal 2024 from a year earlier. The company said it expects Q4 revenue of $124.3 million, up about 17% from a year earlier. Analysts polled by FactSet expect $120.4 million....
Piper Sandler Reviews Tilray's Q2
Piper Sandler Reviews Tilray's Q2
Jan 13, 2025
02:32 PM EST, 01/13/2025 (MT Newswires) -- Tilray reported US$211 million second-quarter revenue, missing Piper Sandler's US$222.2 million estimate. The company's second quarter revenue was up ~6% sequentially. Tilray expects fiscal 2025 sales of US$950 million to US$1 billion, which already included some M&A contribution. We believe TLRY stands out from competitors with direct access to the EU, but we...
Copyright 2023-2026 - www.financetom.com All Rights Reserved